Which combination immunotherapy regimen showed improved overall survival versus chemotherapy in the CheckMate 743 trial for pleural mesothelioma?
-
A
Pembrolizumab + carboplatin
-
B
Nivolumab + ipilimumab
-
C
Atezolizumab + bevacizumab
-
D
Durvalumab + tremelimumab